Preparations of polyalkylene oxide-asparaginase, and methods for manufacturing and using the same.
A polyalkylene oxide-asparaginase composition addresses the limitations of L-asparaginase therapies by reducing antigenicity and prolonging half-life, enhancing its effectiveness in treating leukemia.
JP7857767B2Active Publication Date: 2026-05-13SERVIER IP UK LTD
1 Cites 0 Cited by
Patent Information
- Application Number
- JP2022030538
- Authority / Receiving Office
- JP · JP
- Patent Type
- Patents
- Current Assignee / Owner
- Priority Date
- 2016-06-01
- Filing Date
- 2022-03-01
- Publication Date
- 2026-05-13
- Estimated Expiration
- 2037-06-01
AI Technical Summary
Technical Problem
Existing L-asparaginase therapies face challenges such as high clearance rates and potential immune responses, limiting their efficacy in treating leukemia.
Method used
Development of a polyalkylene oxide-asparaginase composition, which includes a lyophilized, storage-stable formulation with buffers, salts, and sugars, covalently bonding polyalkylene oxide groups to asparaginase to reduce antigenicity and prolong circulation time.
Benefits of technology
The composition achieves reduced immune response and extended half-life, maintaining therapeutic activity over prolonged periods, making it suitable for treating neoplastic conditions like acute myeloid leukemia.
✦ Generated by Eureka AI based on patent content.
Abstract
Embodiments of the present invention include polyalkylene oxide-asparaginase compositions. In some instances, the composition is a lyophilized, storage-stable composition. In some instances, the lyophilized composition includes one or more of a buffer, a salt, and a sugar. Aspects of the invention further include methods for making the composition. The composition finds use in a variety of applications, including, for example, treating a neoplastic condition in a subject.
Need to check novelty before this filing date? Find Prior Art